Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Down 52.9% in March

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 40,400 shares, a decrease of 52.9% from the February 28th total of 85,700 shares. Approximately 2.4% of the shares of the company are sold short. Based on an average daily volume of 2,050,000 shares, the days-to-cover ratio is currently 0.0 days.

Salarius Pharmaceuticals Stock Performance

NASDAQ:SLRX traded down $0.06 during mid-day trading on Friday, hitting $0.86. 115,842 shares of the stock were exchanged, compared to its average volume of 1,256,289. The firm’s 50-day simple moving average is $1.53 and its 200 day simple moving average is $1.58. Salarius Pharmaceuticals has a fifty-two week low of $0.81 and a fifty-two week high of $7.20. The stock has a market capitalization of $1.49 million, a price-to-earnings ratio of -0.11 and a beta of 0.59.

Salarius Pharmaceuticals (NASDAQ:SLRX) last released its quarterly earnings results on Friday, March 21st. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($2.31) by $1.65.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.